Neurim fights to amend Circadin patent amid infringement case against generics

Andrew Fox 2018-11-12 9:19 pm By Miklos Bolza | Sydney

Please login to bookmark

Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au